Even with the identical clinicopathological features, the ability for metastasis is vastly different among triple-negative breast cancer (TNBC) patients. Intratumor heterogeneity (ITH), which is common in breast cancer, may be a key mechanism leading to the tumor progression. In this study, we studied whether a quantitative genetic definition of ITH can predict clinical outcomes in patients with TNBC. We quantified ITH by calculating Shannon index, a measure of diversity in a population, based on Myc, epidermal growth factor receptor/centromeric probe 7 (EGFR/CEP7) and cyclin D1/centromeric probe 11 (CCND1/CEP11) copy number variations (CNVs) in 300 cells at three different locations of a tumor. Among 75 TNBC patients, those who developed metastasis had significantly higher ITH, that is Shannon indices of EGFR/CEP7 and CCND1/CEP11 CNVs. Higher Shannon indices of EGFR/CEP7 and CCND1/CEP11 CNVs were significantly associated with the development of metastasis and were predictive of significantly worse metastasis-free survival (MFS). Regional heterogeneity, defined as the difference in copy numbers of Myc, EGFR or CCND1 at different locations, was found in 52 patients. However, the presence of regional heterogeneity did not correlate with metastasis or MFS. Our findings demonstrate that higher ITH of EGFR/CEP7 and CCND1/CEP11 CNVs is predictive of metastasis and is associated with significantly worse MFS in TNBC patients, suggesting that ITH is a very promising novel prognostic factor in TNBC.
Introduction
Malignant cells can continue to evolve during cancer development and progression, often leading to the generation of genetically and/or phenotypically distinct clones within the same tumor. Such intratumor heterogeneity (ITH) poses significant clinical challenges, including formulation of optimal biopsy strategy, characterization of molecular markers, identification of therapeutic targets and the emergence of resistance to therapy (1) . Technologic advances, including next-generation sequencing approaches, have allowed higher resolution and more detailed characterization of ITH and resulted in a better conceptual understanding of cancer evolution. Accumulating evidences are suggestive of a branched evolution model, such that early acquired mutations are present ubiquitously, whereas subsequent mutational events are found in confined regions or subpopulations (2) (3) (4) .
Although the concept of ITH has been well established, how to integrate the knowledge of ITH into clinical practice remains to be a major challenge. It is plausible that a more heterogeneous population of cancer cells can behave more aggressively, because of probable presence of clones that can proliferate more rapidly, that have higher potential to disseminate, and that are resistant to a specific therapy, etc. However, how to ideally quantify ITH and whether such quantitative measures correlate well with clinical outcome have yet to be defined. While extensive sequencing approaches, for example multiregion sequencing (2, (4) (5) (6) , single cell sequencing (7), ultradeep sequencing (8) , etc., can provide detailed information for understanding ITH, such techniques are not readily applicable clinically, although some data do suggest a potential correlation between higher ITH and worse clinical outcome (5) . Nextgeneration sequencing coupled with skilled quantification was able to measure ITH and link it to clinical outcome in head and neck cancer (9) , but again its clinical application can be difficult due to labor intensity and cost.
Importantly, even heterogeneity of a single genetic event can be clinically significant in identifying patients with poor clinical outcome, as in the case of human epidermal growth factor receptor 2 (HER2) amplification in breast cancer and esophageal cancer (10, 11) . Since it is much easier to analyze these single events, studying ITH of such genetic abnormalities and its clinical significance is particularly attractive. Interestingly, an immunostaining and diversity index calculation based approach showed promises in quantifying ITH and defining its correlation with clinical outcome in breast and esophageal cancers (12, 13) .
In this study, we characterized ITH of CNVs of Myc/8q24, epidermal growth factor receptor (EGFR)/7q12 and cyclin D1 (CCND1)/11q13 in primary tumor samples from 75 triple-negative breast cancer (TNBC) patients, and quantified the degree of ITH by calculating the Shannon index which is reflective of diversity. We further defined that the extent of ITH within the primary tumor predicts distant metastasis and correlates with metastasis-free survival (MFS).
Materials and methods

Patients and TNBC tissue microarray
A convenience cohort of 75 patients newly diagnosed with TNBC in The First Affiliated Hospital of Wenzhou Medical University and The First People's Hospital of Lianyungang, China between April 2005 and March 2014 were included in this study. Inclusion criteria were female sex, age of 18 years or older, without distant metastasis at the time of diagnosis and without neoadjuvant chemotherapy. Formalin-fixed paraffin-embedded primary TNBC samples were used. We firstly performed H&E staining on all the sample tissues to delineate three relative concentrated areas of tumor cells and then obtained tissue samples from the delineated regions to make into tissue microarrays for subsequent processing.
FISH, immunohistochemistry and immunofluorescence
Copy numbers of Myc, EGFR/CEP7 and CCND1/CEP11 were detected by FISH. Expression and subcellular localization of CD44 and CD24 were analyzed using immunohistochemistry and immunofluorescence. Details are provided in Supplementary Methods, available at Carcinogenesis Online.
ITH index
The Shannon index, which estimates the number and distribution of species in a certain geographical area or environmental niche, was used to describe the extent of ITH (12, 14) . In our context, a species represents a cancer cell population with a unique copy number of Myc [bacterial artificial chromosome (BAC) probe counts], or a ratio of EGFR and CCND1 copy number (BAC probe counts) to respective chromosome 7 and 11 copy number [centromeric probe (CEP) counts] (Supplementary Figure 1 is available at Carcinogenesis Online). Copy number data were obtained in 100 individual tumor cells at each of the three sites from each primary tumor sample. Actually, we counted more cells (100 versus 200 versus 300) for each site in five samples, and found that further increasing the cell number did not change the ITH index significantly (data not shown). Considering the easy clinical use, we chose 100 tumor cells for each site in this study. We defined tumor cells in reference to the H&E staining on the continuous sections of tissue microarrays according to the morphology distinct from nontumor cells. For each probe (Myc, EGFR/CEP7, CCND1/CEP11), Shannon index was calculated for each site (100 cells) and also for each primary tumor (300 cells) as follows:
where p i represents the proportion of each species in the tumor sample.
Statistical analysis
Statistical analysis was done in SPSS (v22) and SAS (v9.3). All analyses were two-sided and a P value less than 0.05 was considered statistically significant. Details are provided in Supplementary Methods, available at Carcinogenesis Online.
Results
CNVs of Myc, EGFR and CCND1 in TNBC
We quantify ITH of CNVs using three BAC probes localized to different chromosomal. The BAC probes were selected because these genes are commonly involved in the development of TNBC based on previous studies (15, 16) . CNVs of Myc, EGFR and CCND1 have been frequently reported in breast cancer including TNBC (17) (18) (19) . While copy number itself may be associated with gene expression level (20, 21) and tumor aggressiveness (20) (21) (22) (23) (24) , the diversity of gene copy numbers in cells within a tumor may reflect a particular type of ITH. This ITH of CNVs can be a result of genomic instability, and may potentially correlate with tumor aggressiveness and clinical outcome. We measured copy numbers of Myc/8q24, EGFR/7q12 and CCND1/11q13 in mastectomy specimens by FISH in 75 patients with TNBC. For EGFR and CCND1, chromosome numbers were also measured using centromeric probes for chromosome 7 and 11, respectively, for analysis of relative copy numbers in reference to aneuploidy. Patient characteristics were summarized in Supplementary Table 1, available at Carcinogenesis Online. As a representative, staining ( Figure 1A ) and quantification ( Figure 1B and C) of Myc, EGFR and CCND1 copy numbers in sample T8 were shown in Figure 1 . Copy numbers of each gene were quantified in 100 cells at each of the three sampled sites of the tumor ( Figure 1B and C) . The staining and quantification of three additional representative samples, T45, T10 and T62, were shown in Supplementary Figures 2-4 , available at Carcinogenesis Online, respectively. CNVs were apparent for all three genes, which were indicated by the wide distribution patterns ( Figure 1C 
Regional heterogeneity of CNVs in TNBC
We first compared CNVs of Myc, EGFR and CCND1 at the three different locations in every tumor sample. Kruskal-Wallis H test instead of one-way analysis of variance test was used here, because the difference in copy number distributions was the focus, acknowledging intercellular heterogeneity of gene copy numbers. Data on representative samples were shown in Figure 2 . In sample T1 (Figure 2A ), there were significant differences of Myc, EGFR and CCND1 copy numbers at different locations, indicating the presence of regional heterogeneity. However, in samples T8 ( Figure 2B ), T62 ( Figure 2C ), and T53 ( Figure 2D ), the conclusion of regional heterogeneity was inconsistent for different genes.
Regional heterogeneity of Myc, EGFR and CCND1 copy numbers were summarized in Figure 2E . The presence of regional heterogeneity of Myc copy numbers was not associated with distant metastasis (Table 1) . Similarly, regional heterogeneity of EGFR and CCND1 copy numbers did not correlate with metastasis either (Table 1) . Regional heterogeneity of any gene CNV was found in 52 of the 75 tumors ( Figure 2E ). However, the presence of such regional heterogeneity was also not predictive of the development of metastasis ( Table 1) .
ITH of CNVs in TNBC
Next, we studied ITH of CNVs, that is the diversity of cancer cells in terms of their Myc, EGFR/CEP7 and CCND1/CEP11 copy numbers. We calculated the Shannon index, a measure of diversity in a population, and used it as a quantitative measure of such ITH. A higher Shannon index indicates a more prominent ITH.
At each of the three locations of one tumor, Shannon index was calculated based on Myc copy numbers, as well as EGFR/ CEP7 and CCND1/CEP11 copy number ratios in 100 cells. In limited cases, the Shannon indices for a specific gene CNV were identical at three different sites of the same tumor; however, for the majority of the tumors, variations in Shannon index were present ( Figure 3A ), which may represent regional heterogeneity. We, therefore, combined data from three sites in an attempt to incorporate regional heterogeneity information, and calculated Shannon index based on gene copy numbers in the entire 300 cells for each tumor ( Figure 3A , red dots). Shannon index of Myc copy numbers varied in different tumor samples. Same is true for Shannon indices of EGFR/CEP7 and CCND1/CEP11 copy number ratios.
ITH of CNVs correlates with development of metastasis in TNBC patients
After a median follow-up of 71 months (range 10-134), 20 of 75 patient developed distant metastasis. Interestingly, patients who developed metastasis appeared to have higher Shannon index ( Figure 3B ). To confirm this, we quantitatively compared the Shannon index of each probe in patients with and without metastasis. As shown in Figure 3C , it was obvious that patients who developed metastasis had higher Shannon index of Myc copy numbers (1.36 ± 0.07 versus 1.18 ± 0.05, P = 0.054) as well as EGFR/CEP7 (1.29 ± 0.09 versus 0.98 ± 0.03, P < 0.001) and CCND1/CEP11 copy number ratios (1.74 ± 0.07 versus 1.53 ± 0.04, P = 0.011). As shown in Table 1 , using a cutoff value near the median, we found that higher Shannon indices of EGFR/CEP7 (≥1.0) and CCND1/CEP11 (≥1.6) copy number ratios significantly correlated with the development of metastasis. There was also a clear trend that a higher (≥1.2) Shannon index of Myc copy numbers correlated with metastasis. In addition, a higher sum Shannon index (≥3.8) significantly correlated with the development of metastasis.
Of note, positive lymph node status also correlated with metastasis, but none of the other traditional prognostic factors including age, tumor size, Ki-67, grade, stage and adjuvant chemotherapy was found to correlate with the development of metastasis. This is likely because of the small sample size. In this context, ITH of CNVs showed a great promise as a novel prognostic factor to predict metastasis of TNBC. 
ITH of CNVs correlates with MFS in TNBC patients
With a median follow-up of 50.5 months, we found that patients with a higher Shannon index of Myc copy numbers (≥1.2) had shorter MFS ( Figure 3D ). Although the difference did not reach statistical significance, the trend was clear. Patients with higher Shannon indices of EGFR/CEP7 (≥1.0) and CCND1/CEP11 (≥1.6) copy number ratios had statistically significantly worse MFS ( Figure 3D ). Using similarly conducted log-rank tests, we found that patients with positive lymph node status had shorter MFS, and the other traditional prognostic factors were not predictive of MFS (Table 2 ). As shown in Table 2 , in Cox regression models, traditional prognostic factors except for lymph node status did not correlate with MFS. Higher Shannon index of Myc copy numbers (≥1.2) had a trend to predict worse MFS. Patients with higher Shannon indices of EGFR/CEP7 (≥1.0) and CCND1/CEP11 (≥1.6) copy number ratios had statistically significantly worse MFS. Additionally, a higher sum Shannon index correlated with shorter MFS. Of note, presence or absence of regional heterogeneity did not affect MFS.
Cancer stem cell enrichment does not correlate with metastasis of TNBC
In addition to ITH, cancer stem cell (CSC) phenotype is another promising molecular marker in predicting the outcome. It may be easy to understand that the more CSCs, the more likely tumors are able to survive from challenges such as chemotherapy, radiotherapy, immune system, etc. Moreover, CSC hypothesis is one of the two main models explaining the generation of inter-and intratumor heterogeneity. Here, we intend to investigate whether ITH is related to CSC enrichment and compare the performance of ITH with CSC in predicting clinical outcome.
It is well known that in breast cancer, CD44 + /CD24 − cells have stem cell-like characteristics (25) . We performed immunohistochemistry and immunofluorescence staining of CD44 and CD24 at each of the three sites of the 75 tumor samples and determined the CSC phenotype of the tumors. Figure 4A is a representative staining of sample T69, with a strong CD44 staining and weak CD24 staining. Using >10% expression on immunohistochemistry as the cutoff (26, 27) , CSC phenotype was determined at each site of every tumor ( Figure 4B ). In most cases, the phenotypes at different locations were consistent. If discrepancy was found, the CSC phenotypes of two consistent locations were used for the tumor ( Figure 4C ). Although CSCs were thought to be associated with more aggressive tumor behaviors (28, 29) , we found that the CSC phenotype did not correlate with metastasis of TNBC in this study (Table 1) . Although patients with the CSC phenotype had a trend of decreased MFS, the difference was not statistically significant ( Figure 4D and Table 2 ). Interestingly, tumors with the CSC phenotype had comparable Shannon indices of Myc copy numbers and EGFR/CEP7 and CCND1/CEP11 copy number ratios ( Figure 4E ), suggesting that there was no clear association between ITH and CSC phenotype.
Discussion
ITH has been increasingly recognized and may have clinical significance in diagnosis, management and prognosis of cancer (1, 2, 5) . How to assess such heterogeneity within a tumor and clinically use this information remains a big challenge. DNA sequencing based approach has enabled the conceptual understanding of genetic ITH and tumor evolution and progression (6, 7, 30 Table 1 . Continued multiregional or even single cell whole genome sequencing can be overwhelming to clinicians. The labor intensity and high cost also pose an obstacle for such an approach to be applied clinically. At present, perhaps more simplified approaches with higher cost-effectiveness will be more attractive in terms of clinical applicability. This can be important particularly in developing countries. In this study, we found that the ITH of single genetic events, that is CNVs of certain genes, can be readily quantified and correlates well with clinical outcome of TNBC. A higher Shannon index, indicative of the higher diversity of cells, of CNVs of EGFR and CCND1 in TNBC strongly correlates with a significantly higher probability of metastasis and significantly worse MFS of TNBC patients. Adding treatment status to the adjusted covariate in addition to age, stage and grade did not change the results and conclusions in this study (data not shown). However, we advise cautious interpretation of the results since limited to the small sample size in each group; we did not conduct analysis adjusting for the critical factors such as obesity, diet and menopausal status, which could also have an impact on the association between ITH and cancer prognosis. We also took a look at the diversity index in four adjacent normal tissues to ensure the observed ITH was not caused by technical issues and found that diversity index of normal tissues was universally lower compared with the paired tumor tissues for each probe analyzed (data not shown). Our study demonstrates that properly quantified ITH of single genetic events by appropriate probes can be a promising prognostic factor of clinical outcome and survival of cancer patients, and subsequently contributes to the early design of more effective treatment strategies. Importantly, this proof of concept study illustrates the feasibility of predicting the risk of metastasis by simplified approaches that can be easily applied clinically.
Regional heterogeneity, at least in theory, represents a common type of ITH, such that cells at different anatomical locations within the same tumor may have a different molecular signature and clinical behavior. This may significantly affect diagnostic efforts, that is whether a multiregional biopsy approach should be adopted in order to more comprehensively and accurately characterize the tumor at a molecular level (gene mutations, biomarker expression, etc.). Interestingly, regional heterogeneity appears to vary in different types of tumors. For example clinically important mutations appear to distribute in separate regions of clear cell renal cell carcinoma (2), but most known cancer gene mutations may occur early and are present in all cells in lung adenocarcinoma (5) . In breast cancer, the point mutations and rearrangements affecting the most common breast cancer genes occur early in some tumors and late in others, without a strict temporal order (4). In our study, we compared CNVs of Myc, EGFR and CCND1 at three different sites within the same tumor and found that majority of the tumors had regional heterogeneity of CNVs of at least one of the three probes. Therefore, multiregional sampling might be more appropriate in TNBC. A high prevalence of regional heterogeneity in TNBC will likely preclude its clinical application as a prognostic factor. In fact, regional heterogeneity of CNVs of any of the three genetic probes did not correlate with metastasis of TNBC in our study.
Although ITH of CNVs of Myc, EGFR and CCND1 measured by Shannon index appears to be a promising prognostic factor in TNBC, the best methodology is yet to be defined. One consideration is single versus double probe. We did not have a CEP as an internal reference for Myc/8q24 due to unavailability so that no comparison can be made. For EGFR/CEP7, we found that ITH of BAC and CEP copy number alone also correlated with metastasis and MFS (Supplementary Figure 5A and C is available at Carcinogenesis Online). However, this was not true in the case of CCND1/CEP11 (Supplementary Figure 5B and D is available at Carcinogenesis Online). Based on our results, we suggest that a double probe (both BAC and CEP) staining approach may perform better clinically in determining ITH and predicting the outcome. The other consideration is whether using multiple probes together would help. In our study, with a limited sample size, sum Shannon index of two or three probes significantly correlated with metastasis ( Prognostic factors in TNBC have been widely studied. Traditional prognostic factors included age, tumor size, lymph node status, chemotherapy, etc. (31) (32) (33) . Some novel molecular prognostic factors including p53, gene expression, pathway activation, gene signature have also been reported (34) (35) (36) (37) (38) (39) . In our study, however, some traditional prognostic factors including age, tumor size, Ki-67, grade, stage and adjuvant chemotherapy did not correlate with metastasis or MFS in TNBC, likely due to limited sample size. Another potential prognostic factor in breast cancer is CSC phenotype. It was postulated that CSCs are pluripotent and are critical in forming metastatic lesions (40, 41) , and the enrichment of CSCs in a tumor may be therefore predictive of metastasis. In breast cancer, a CD44 + /CD24 − signature is thought to be a characteristic of stem or stem-like cells (25, 42) , and CD44 and CD24 have been shown to be prognostic factors in some studies (43, 44) . In our study, we found that enrichment of CSCs did not correlate with metastasis or MFS either. In this context, ITH of CNVs of EGFR/CEP7 and CCND1/CEP11 was significantly associated with metastasis and MFS, and ITH of CNVs of Myc also showed promise in predicting metastasis and MFS. It may not be surprising that ITH can predict metastasis because the more heterogeneous the cancer cells are, the more likely the tumor will harbor cells that are capable of initiating distant dissemination. But we need to prove this concept before clinical application. Here, we defined a quantitative measure of ITH that correlates with clinical outcome. What's interesting is that ITH showed a great potential in predicting metastasis when traditional prognostic factors and a presumed CSC signature did not perform well in this small sized study. The ITH of CNVs represents intercellular heterogeneity and may reflect genomic instability of the tumor. Since both cell population diversity and genetic stability of a tumor are likely associated with tumor aggressiveness, our findings are less likely results of coincidence. ITH is, therefore, a very promising novel prognostic factor of TNBC, and warrants further study in breast cancer.
We chose Myc, EGFR/CEP7 and CCND1/CEP11 as probes in this study. However, the ITH measured by Shannon index only reflected cellular heterogeneity and was not associated with any of the biological functions of the above genes in TNBC. With appropriate probes or marker, such an approach can potentially be used in other types of breast cancer and other cancers as well. Expansion of study in larger populations is necessary before clinical application.
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Supplementary data are available at Carcinogenesis online. 
